Skip to main content

Advertisement

Table 2 Differences of indexes in patients with different treatment method

From: Evaluation of treatments for sacroiliitis in spondyloarthropathy using the Spondyloarthritis Research Consortium Canada scoring system

Index Baseline (mean ± SD) Post-treatment (mean ± SD) t/Z P
Patients treated by anti-TNF alone (n = 18)a
 SPARCC 27.76 ± 18.38 14.38 ± 14.91 2.681 0.011
 ASDAS 2.56 ± 1.24 1.83 ± 0.71 4.231 0.006
 ESRb 27.94 ± 33.24 5.72 ± 7.06 –2.763 0.009
 CRPb 16.29 ± 23.05 2.70 ± 2.55 –2.470 0.022
Patients treated by anti-TNF combined with DMARDs (n = 21)c
 SPARCC 39.53 ± 19.21 20.71 ± 15.98 5.110 0.000
 ASDAS 3.58 ± 1.05 1.88 ± 0.74 4.278 0.003
 ESRb 38.49 ± 38.50 9.02 ± 13.29 –2.703 0.010
 CRPb 26.29 ± 28.02 8.43 ± 15.79 –2.329 0.053
Patients treated by DMARDs alone (n = 17)d
 SPARCC 28.67 ± 15.51 21.66 ± 11.23 0.820 0.419
 ASDAS 2.21 ± 1.03 1.99 ± 0.47 1.301 0.261
 ESRb 12.14 ± 8.43 4.65 ± 4.27 –2.396 0.013
 CRPb 7.919 ± 5.60 5.55 ± 4.46 –1.911 0.056
  1. aBaseline of clinical practices from patients in anti-TNF group: 85.7 % male; age, 23.3 ± 6.43; symptom duration, 3.15 ± 2.98; HLA-B27-positive, 100 %
  2. bNot normally distributed, compared by paired rank test
  3. cBaseline of clinical practices from patients in combination group: 82.35 % male; age, 21.6 ± 3.36; symptom duration, 2.97 ± 2.69; HLA-B27-positive, 88.2 %
  4. dBaseline of clinical practices from patients in DMARD group: 80 % male; age, 20.5 ± 2.75; symptom duration, 3.0 ± 2.66; HLA-B27-positive, 90 %
  5. ASDAS Ankylosing Spondylitis Disease Activity Indices, CRP C-reactive protein, DMARD disease-modifying anti-rheumatic drug, ESR erythrocyte sedimentation rate, SD standard deviation, SPARCC Spondyloarthritis Research Consortium Canada, TNF tumor necrosis factor